ACC 2015: AstraZeneca optimistic on Brilinta after PEGASUS, others less so

AstraZeneca's US president Paul Hudson is optimistic about the opportunities for Brilinta (ticagrelor) in longer-term treatment of acute coronary syndrome (ACS) based on results from the Phase III PEGASUS clinical trial, but analysts and doctors are concerned about the bleeding risk associated with the drug.